Public Assessment Report. Decentralised Procedure

Transcription

1 Public Assessment Report Decentralised Procedure BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS (bosentan monohydrate) Procedure No: UK/H/4965/ /DC & UK/H/5232/001-2/DC UK Licence No: PL 17780/ , 0610 Winthrop Pharmaceuticals UK Limited

2 LAY SUMMARY On 23 June 2013, Poland, Romania, Slovenia, Hungary and the UK agreed to grant Marketing Authorisations to Winthrop Pharmaceuticals UK Limited for the medicinal products Bosentan Zentiva 62.5 mg & 125 mg film-coated tablets (PL 17780/ ; UK/H/4965/001-2/DC). In a parallel procedure France, Italy, Cyprus, Spain, Portugal, Germany and the UK also agreed to grant Marketing Authorisations for these products (PL 17780/0571, 0610; UK/H/5232/001-2/DC). The licences were granted via the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS). After the national phase, Marketing Authorisations were granted in the UK on 24 July These are prescription-only medicines (legal status POM), containing the active ingredient bosentan monohydrate. Bosentan tablets belong to a class of medicines called endothelin receptor antagonists and are used to treat pulmonary arterial hypertension (PAH). PAH is high blood pressure in the pulmonary arteries, the blood vessels that carry blood from the heart to the lungs. Bosentan widens the pulmonary arteries, making it easier for the heart to pump blood through them. This lowers the blood pressure and relieves the symptoms. No new or unexpected safety concerns arose from this application and it was, therefore, judged that the benefits of taking Bosentan Zentiva 62.5 mg & 125 mg film-coated tablets outweigh the risks and Marketing Authorisations were granted. 2

3 TABLE OF CONTENTS Module 1: Information about initial procedure Page 4 Module 2: Summary of Product Characteristics Page 5 Module 3: Patient Information Leaflet Page 6 Module 4: Labelling Page 7 Module 5: Scientific discussion during initial assessment Page 11 I II III III.1 III.2 III.3 IV Introduction About the product Scientific overview and discussion Quality aspects Non-clinical aspects Clinical aspects Overall conclusion and benefit-risk assessment Module 6: Steps taken after initial procedure Page 20 3

4 Module 1 Information about initial procedure Product Name Bosentan Zentiva 62.5 mg film-coated tablets Bosentan Zentiva 125 mg film-coated tablets Type of Application Generic, Article 10(1) Active Substances Form Strength MA Holder Reference Member State (RMS) Concerned Member States (CMS) Procedure Number Bosentan monohydrate Film-coated tablets 62.5 mg and 125 mg Winthrop Pharmaceuticals UK Limited One, Onslow Street Guildford Surrey GU1 4YS United Kingdom UK UK/H/4965/001-2/DC: Poland, Romania, Slovenia and Hungary UK/H/5232/001-2/DC: France, Italy, Cyprus, Spain, Portugal, Germany UK/H/4965/001-2/DC UK/H/5232/001-2/DC Timetable Day June

5 Module 2 Summary of Product Characteristics In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPCs) for products that have been granted Marketing Authorisations at a national level are available on the MHRA website. 5

6 Module 3 Patient Information Leaflet In accordance with Directive 2010/84/EU the Patient Information Leaflets for products that are granted Marketing Authorisations at a national level are available on the MHRA website. 6

7 Module 4 Labelling The following text is the approved label text for Bosentan Zentiva 62.5 mg film-coated tablets (PL 17780/0569; UK/H/4965/001/DC). The approved label text for Bosentan Zentiva 62.5 mg filmcoated tablets (PL 17780/0571; UK/H/5232/001/DC) is consistent with this. No label mock-ups have been provided for these products. In accordance with medicines legislation, these products shall not be marketed in the UK until approval of the label mock-ups has been obtained. 7

8 8

9 The following text is the approved label text for Bosentan Zentiva 125 mg film-coated tablets (PL 17780/0570; UK/H/4965/002/DC). The approved label text for Bosentan Zentiva 125 mg filmcoated tablets (PL 17780/0610; UK/H/5232/002/DC) is consistent with this. No label mock-ups have been provided for these products. In accordance with medicines legislation, these products shall not be marketed in the UK until approval of the label mock-ups has been obtained. 9

10 10

11 Module 5 Scientific discussion during initial procedure I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the member states considered that the applications for Bosentan Zentiva 62.5 mg & 125 mg film-coated tablets (PL 17780/ , 0610; UK/H/4965/001-2/DC and UK/H/5232/001-2/DC) could be approved. The applications were submitted via the Decentralised Procedure, with the UK as Reference Member State (RMS), and the following Concerned Member States (CMS): UK/H/4965/001-2/DC: Poland, Romania, Slovenia and Hungary UK/H/5232/001-2/DC: France, Italy, Cyprus, Spain, Portugal, Germany These products are prescription-only medicines (legal classification POM). These applications were submitted according to Article 10(1) of Directive 2001/83/EC, as amended, claiming to be generic medicinal products of Tracleer 62.5 mg and 125 mg film-coated tablets (Actelion Registration Limited, UK), which were initially granted Marketing Authorisations in the EU, via the Centralised Procedure, on 15 May The reference product used in the bioequivalence study was Tracleer 125 mg film-coated tablets (Actelion Registration Limited, UK). Bosentan Zentiva 62.5 mg & 125 mg film-coated tablets are indicated for treatment of pulmonary arterial hypertension (PAH). Efficacy has been shown in primary (idiopathic and heritable) PAH, PAH secondary to scleroderma (without significant interstitial pulmonary disease) and PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger s physiology. The neurohormone endothelin-1 (ET-1) is one of the most potent vasoconstrictors known. It can also promote fibrosis, cell proliferation, cardiac hypertrophy and remodelling, and is pro-inflammatory. These effects are mediated by endothelin binding to endothelin A and B (ETA and ETB) receptors located in the endothelium and vascular smooth muscle cells. ET-1 concentrations in tissues and plasma are increased in several cardiovascular disorders and connective tissue diseases. In the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with the severity and prognosis of pulmonary arterial hypertension and heart failure. Bosentan is a dual endothelin receptor antagonist with affinity for both ETA and ETB receptors. By specifically antagonising these receptors, Bosentan decreases both pulmonary and systemic vascular resistance, resulting in increased cardiac output without increasing heart rate. No non-clinical studies and, with the exception of the bioequivalence study, no new clinical studies were conducted, which is acceptable given that the application was based on being a generic medicinal product of an originator product that has been licensed for over 10 years. A bioequivalence study was performed, which compared the pharmacokinetics of the test product, Bosentan Zentiva 125 mg film-coated tablets to those of the reference product, Tracleer 125 mg filmcoated tablets (Actelion Registration Limited, UK). The bioequivalence study was carried out in accordance with Good Clinical Practice (GCP). The RMS has been assured that acceptable standards of Good Manufacturing Practice are in place for these product types at all sites responsible for the manufacture, assembly and batch release of these products. The RMS and CMS considered that the applications could be approved with the end of the procedure on 23 June After a subsequent national phase, licences were granted in the UK on 24 July

12 II. ABOUT THE PRODUCT Name of the product in the Reference Member State Name(s) of the active substance(s) (INN) Pharmacotherapeutic classification (ATC code) Pharmaceutical form and strength(s) Reference numbers for the Decentralised Procedure Reference Member State Member States concerned Bosentan Zentiva 62.5 mg film-coated tablets Bosentan Zentiva 125 mg film-coated tablets Bosentan monohydrate Antihypertensives, other antihypertensives (C02KX01) Film-coated tablets 62.5 mg and 125 mg UK/H/4965/001-2/DC UK/H/5232/001-2/DC UK UK/H/4965/001-2/DC: Poland, Romania, Slovenia and Hungary UK/H/5232/001-2/DC: France, Italy, Cyprus, Spain, Portugal, Germany Marketing Authorisation Number(s) PL 17780/ , 0610 Name and address of the authorisation holder Winthrop Pharmaceuticals UK Limited One, Onslow Street Guildford Surrey GU1 4YS United Kingdom 12

13 III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 QUALITY ASPECTS S. Active substance Bosentan monohydrate rinn: Bosentan monohydrate Chemical name: 4-(1,1-Dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'- bipyrimidin]-4-yl]benzene sulfonamide monohydrate. Structure: 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2- methoxy phenoxy)-2-(2-pyrimidinyl)- 4- pyrimidinyl]benzene-1- sulfonamide monohydrate Molecular formula: C 27 H 29 N 5 O 6 S H 2 O Molecular weight: Appearance: White to yellowish powder, which is freely soluble in acetone; soluble in ethanol, in ethyl acetate, in dichloromethane and in acetonitrile; sparingly soluble in toluene; slightly soluble in methanol; and practically insoluble in water and in cyclohexane An Active Substance Master File (ASMF) has been provided by each active substance manufacturer, covering the manufacture and control of the active substance bosentan monohydrate. Synthesis of the drug substance from the designated starting materials has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are in place for all starting materials and reagents and these are supported by relevant certificates of analysis. Appropriate proof-of-structure data have been supplied for the active substance. All potential known impurities have been identified and characterised. An appropriate specification is provided for the active substance. Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications. Satisfactory Certificates of Analysis have been provided for all working standards. Batch analysis data are provided and comply with the proposed specification. Suitable specifications have been provided for all packaging used. The primary packaging has been shown to comply with current guidelines concerning contact with food. Appropriate stability data have been generated supporting a suitable retest period when stored in the proposed packaging. 13

14 P. Medicinal Product Other Ingredients Other ingredients consist of the pharmaceutical excipients, as follows: Tablet core: maize starch, povidone (K-30), sodium starch glycolate (type B), pregelatinized maize starch, glycerol dibehenate, magnesium stearate Coating: Opadry II 85F Orange (consisting of polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, yellow iron oxide (E 172), red iron oxide (E 172)) With the exception of the Opadry Orange coating agent, which complies with suitable in-house standards, all excipients comply with their respective European Pharmacopoeia monographs. In addition, the yellow iron oxide (E 172) and red iron oxide (E 172) are in compliance with current EU Directives concerning the use of colouring agents. None of the excipients are sourced from animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of this product. Pharmaceutical Development The objective of the development programme was to formulate globally acceptable, stable and bioequivalent products that could be considered generic medicinal products of the currently licensed products, Tracleer 62.5 mg and 125 mg film-coated tablets (Actelion Registration Limited). A satisfactory account of the pharmaceutical development has been provided. Comparative in vitro dissolution and impurity profiles have been provided for the proposed products and their respective reference products. Manufacturing Process Satisfactory batch formulae have been provided for the manufacture of the products, along with an appropriate account of the manufacturing process. Suitable in-process controls are in place to ensure the quality of the finished products. Process validation has been carried out on three pilot-scale batches of each strength of finished product. The results are satisfactory. The marketing authorisation holder has committed to providing process validation data from production-scale batches as soon as these are available. Finished Product Specification The finished product specifications proposed are acceptable. Test methods have been described and have been adequately validated. Batch data have been provided and comply with the release specifications. Certificates of analysis have been provided for all working standards used. Container-Closure System The finished product is packaged in either polyvinylchloride/polyethylene/polyvinylidene chloride/aluminium blister packs or oriented polyamide/aluminium/polyvinylchloride/aluminium foil blister packs in pack sizes of 14, 56 or 112 tablets. The Marketing Authorisation Holder has stated that not all pack sizes are intended for marketing. However, they have committed to providing the relevant licensing authority with the mock-ups for any pack size before marketing it in that country. Satisfactory specifications and certificates of analysis have been provided for all packaging components. All primary packaging complies with the current European regulations concerning materials in contact 14

15 with food. Stability of the product Stability studies were performed, in accordance with current guidelines, on batches of finished product manufactured by the finished product manufacturer and packed in the packaging proposed for marketing. The results from these studies support a shelf-life of 24 months, with no special storage conditions. Bioequivalence/bioavailability A bioequivalence study was performed, which compared the pharmacokinetics of the test product, Bosentan Zentiva 125 mg film-coated tablets to those of the reference product, Tracleer 125 mg film-coated tablets (Actelion Registration Limited, UK). Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labels The SmPCs, PILs and labels are acceptable from a pharmaceutical perspective. A bridging report referring to the results of consultations with target patient groups ( user testing ), in accordance with Article 59 of Council Directive 2001/83/EC (as amended) for the package leaflet for the product Ezetimibe Zentiva 10 mg tablets (Zentiva, k.s., Prague, Czech Republic) was provided. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains. Marketing Authorisation Application (MAA) form The MAA forms are satisfactory from a pharmaceutical perspective. Quality Overall Summary (Expert report) The pharmaceutical expert report has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical dossier. Conclusion The grant of Marketing Authorisations is recommended. 15

16 III.2 NON-CLINICAL ASPECTS As the pharmacodynamic, pharmacokinetic and toxicological properties of bosentan monohydrate are well-known, no further non-clinical studies are required and none have been provided. The applicant s non-clinical expert report has been written by an appropriately qualified person and is satisfactory, providing an appropriate review of the product s pharmacology and toxicology. Suitable justification has been provided for the non-submission of an environmental risk assessment. As these products are intended for generic substitution with products that are currently marketed, no increase in environmental burden is expected. There are no objections to the approval of these products from a non-clinical viewpoint. III.3 CLINICAL ASPECTS Pharmacokinetics In support of these applications, the Marketing Authorisation Holder has submitted the following bioequivalence study: A randomised, open-label, 4-way replicate crossover study, comparing the pharmacokinetics of the test product Bosentan Zentiva 125 mg film-coated tablets to those of the reference product, Tracleer 125 mg film-coated tablets (Actelion Registration Limited, UK) in healthy adult subjects, under fasting conditions. Volunteers were given each treatment after a supervised fast of at least 10 hours. Blood samples were collected for the measurement of pharmacokinetic parameters pre-dose and up to 36 hours post dose. Each regimen was separated by a 7-day washout period. The pharmacokinetic results are presented in the tables below: 16

17 Compared with the reference product, the 90 % confidence intervals for the test product are within the bioequivalence acceptance limits of % for C max and AUC. Bosentan Zentiva 125 mg film-coated tablets can, therefore, be considered bioequivalent with Tracleer 125 mg film-coated tablets. As the 62.5 mg and 125 mg strengths of the product meet the bio-waiver criteria specified in the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1/Corr**) the results and conclusions of the bioequivalence study on the 125 mg strength can be extrapolated to the 62.5 mg film-coated tablets. Efficacy No new data on efficacy have been submitted and none are required for this type of application. Safety With the exception of the data submitted during the bioequivalence study, no new safety data were submitted and none were required. No new or unexpected safety issues were raised by the bioequivalence data. SmPC, PIL and Labels The SmPCs, PILs and labels are acceptable from a clinical perspective. 17

18 Pharmacovigilance System and Risk Management Plan The Pharmacovigilance System, as described by the applicant, fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance, and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. A suitable risk management plan has been provided for these products. Clinical Expert Report The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. Conclusion The grant of Marketing Authorisations is recommended. IV OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT QUALITY The important quality characteristics of Bosentan Zentiva 62.5 mg & 125 mg film-coated tablets are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit-risk balance. NON-CLINICAL No new non-clinical data were submitted and none are required for applications of this type. CLINICAL Bioequivalence has been demonstrated between the applicant s product, Bosentan Zentiva 125 mg filmcoated tablets and the reference product, Tracleer 125 mg film-coated tablets. As the 62.5 mg and 125 mg strengths of the product meet the bio-waiver criteria specified in the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1/Corr**) the results and conclusions of the bioequivalence study on the 125 mg strength can be extrapolated to the 62.5 mg film-coated tablets. No new or unexpected safety concerns arose from these applications. The SmPCs, PILs and labelling are satisfactory and consistent with those for the reference product. BENEFIT-RISK ASSESSMENT The quality of the products is acceptable, and no new non-clinical or clinical safety concerns have been identified. Bioequivalence has been demonstrated between the applicant s products and the reference products. Extensive clinical experience with bosentan monohydrate is considered to have demonstrated the therapeutic value of the compound. The benefit-risk assessment is therefore considered to be positive. 18

19 Module 6 STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY Date submitted Application type Scope Outcome 19